key: cord-0989487-mqg6ndu0
authors: Bradley, Elisa A.; Boucly, Athénaïs; Benza, Raymond L.
title: Ethical Considerations of Thoracic Transplant and Circulatory Support during the COVID-19 Pandemic: A Closer Look at Pulmonary Vascular Disease
date: 2020-06-06
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2020.05.014
sha: afce1272d7ba4b38f837b95a311e3c2c1a18ba46
doc_id: 989487
cord_uid: mqg6ndu0

nan

The global consequences of SARS-CoV-2 infection have impacted hospital resources including the availability of medical personnel, general and intensive care beds and personal protective equipment (PPE), to name a few. In an effort to preserve PPE, personnel and inpatient beds, non-emergent procedures and surgeries have largely been electively postponed in many centers. Therefore, it is important to consider the ethical consequences regarding thoracic transplant and circulatory support during the COVID-19 pandemic. These consequences extend to all cardiovascular and pulmonary disease processes that may ultimately be refractory to medical therapy, and culminate in end-stage heart failure or respiratory failure, and this includes severe pulmonary vascular disease (pulmonary arterial hypertension; PAH).

The ISHLT COVID-19 Taskforce publication by Holm et. al. outlines proposed stages of the pandemic, with respect to healthcare system utilization, and considers ethical principles that should be evaluated during the pandemic, as set forth by the Organ Procurement and Transplantation Network (OPTN) inclusive of utility, justice and respect for persons. 1 We propose here that, perhaps there are some "carve-out" groups, such as PAH, that require unique consideration during the pandemic. The Organ Procurement and Transplantation Network (OPTN) has proposed that the major ethical principals applicable to promotion of equitable outcomes in organ allocation and transplant should include: "utility", "justice" and "respect for persons". 2 In the broadest sense, "utility" takes into account the amount, and probability of benefit and risk, as it relates to the overall potential population impact, in this case related to specialized PAH testing and therapy, as well as thoracic organ transplant. "Justice", on the other hand, describes the objective (fair) dissemination of these resources and/or thoracic organ transplant. Here we review the specific principles and effects in the PAH patient first, as they relate to the availability of specialized testing and treatment, and second with respect to organ allocation and transplant during the pandemic.

In the face of the current pandemic, one of the challenges that arises in the care of PAH patients, is the ability to admit those requiring invasive hemodynamic testing which includes those with either 1) a new diagnosis of PAH or 2) declining functional capacity. This is critically important, as these patients derive significant benefit ("utility") from early initiation and/or titration of PAH-specific medication. Given that delaying initiation or titration of PAH therapy leads to increased morbidity and mortality, in the current proposed stages of the pandemic, it is likely that invasive hemodynamic testing in patients with suspected new or worsening PAH, should not be restricted. It is worth mentioning that these procedures may be done either outpatient or inpatient, depending on the individual degree of illness. Importantly, it would be rare that hospitalization of PAH patients requiring invasive hemodynamic testing would compromise intensive care beds, which are best conserved for patients with active COVID-19 infection, thus avoiding any competition between the PAH patient requiring this evaluation and those needing COVID-19 care, therefore complying with "just" allocation of testing/treatment resources. Timely initiation of PAH therapy and/or medication titration, may theoretically reduce the future need for intensive care in this group, and therefore prioritization of this work-up may be particularly important when resources such as intensive care beds, are scarce. Consultation with an expert and specialized pulmonary hypertension team would be useful to help determine which patients would benefit from this approach.

Advanced resource allocation for the PAH patient, including mechanical support and organ transplant, has been questioned with respect to the principle of "utility". This is largely driven by the concern that PAH patients are high-risk, and have increased potential for post-transplant graft dysfunction and increased resource utilization. 8 However, some studies have demonstrated that up-front risk stratification of PAH patients according to estimates of 1-year mortality, can correctly identify which subset of PAH patients may benefit most, while minimizing overall risk and resource utilization. 4, 5, 9 It will be crucially important to identify those PAH patients that have a reasonable perspective for recovery. One way to assess this, is to determine which PAH patients have low to intermediate calculated 1-year mortality (such as using the REVEAL 2.0 score (< 8 is favorable). Perhaps this small subset of PAH patients should continue to be considered for mechanical support and/or transplant, irrespective of PAH itself, however noting that this will require ongoing input and assessment from the advanced transplant team, weighing risks/benefits and considering similar parameters in other individuals concurrently listed, to identify those patients with the best chance for full recovery and least resource utilization ("utility").

We must also consider the effects of COVID-19 on the PAH patient more specifically.

It's not entirely clear whether or not patients with underlying pulmonary disease and PAH do worse with COVID-19. 3 Therefore, it is not likely fair ("justice") to impart resource restriction to the PAH patient listed for transplant during the pandemic, based upon disease-process alone. Reflecting further on PAH, one must consider the unique pathophysiologic consequences inflicted upon the cardiovascular and pulmonary systems in those infected with COVID-19. Indeed, both the disease itself, and subsequent treatment (ventilation and PEEP), have profound adverse affects on the right ventricle (RV), which in many cases is already adversely remodeled in PAH. Thus it would be anticipated that PAH patients with COVID would not fare well and that resourse allocation might be best utilized for others. Conversely, given that significant endothelial dysfunction and vascular complications are implicated in COVID-19, theoretically PAH specific medications may be beneficial, as they target endothelial function and off-load the RV. 4, 5 In addition, several PAH specific therapies may also impart direct anti-coronaviridae viral effects. 6, 7 In summary, operational ethical principles applied to the overarching cardiovascular and pulmonary transplant groups should equally extend to those with an underlying diagnosis of pulmonary vascular disease. It is important to maintain accessibility to invasive hemodynamic testing in those patients with new and/or suspected worsening of PAH despite the stage of the current pandemic. Finally, advanced resources such as mechanical circulatory support and organ transplant may be considered in a small subset of PAH patients identified as having a reasonable perspective of recovery, and if overall vetted risk amongst other recipients remains relatively low.

Ethical Considerations regarding Heart and Lung Transplantation and Mechanical Circulatory Support during the COVID-19 Pandemic: An ISHLT COVID-19 Taskforce Statement

Ethical Principles to be Considered in the Allocation of Human Organs

Do chronic respiratory diseases or their treatment affect the risk fo SARS-CoV-2 infection? The Lancet Respiratory Medicine

ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies

Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound

Clinical risk factors for primary graft dysfunction after lung transplantation

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. The European respiratory journal